Gilead Sciences Stock - Cantor Fitzgerald reiterates Overweight rating

Gilead Sciences remains in analyst focus after Cantor Fitzgerald reiterated its Overweight rating and $155 price target. On Wednesday, the stock trades below the consensus target, while investors also watch ongoing developments in the company’s antiviral and oncology portfolio.

Edited by ad hoc news Operations & Strategy Desk. Verified prior to publication on 06/17/2026, 20:34 UTC. Details in the imprint.

Gilead Sciences (US3755581036) drew fresh analyst attention this week after Cantor Fitzgerald reiterated its Overweight rating and a $155 price target on the stock, according to an analyst note published on Tuesday. Cantor’s update was reported by Investing.com.

What Cantor Fitzgerald said

Cantor Fitzgerald kept its Overweight rating on Gilead Sciences and confirmed a $155 price target, signaling continued confidence in the company’s earnings outlook and pipeline. The note highlighted valuation support at current levels.

According to the report, Gilead Sciences shares most recently traded around $127, implying notable upside to Cantor’s target if the firm’s thesis plays out over the coming 12 months. MarketBeat data show a similar upside in the broader consensus.

Analyst consensus on the stock

Beyond Cantor’s call, Gilead Sciences carries an average rating of “Moderate Buy” from 29 Wall Street analysts, with a consensus 12-month price target of $158.41, according to MarketBeat. The highest target stands at $180 and the lowest at $122.

That consensus implies roughly mid-20s percentage upside from the latest closing price near $127, underscoring that most covering banks still see value in Gilead Sciences stock despite a mature HIV franchise.

How Gilead Sciences makes its money

Gilead Sciences generates the bulk of its revenue from antiviral therapies, led by HIV combinations such as Biktarvy and Veklury for COVID-19, and is investing heavily in oncology, particularly cell therapies like Yescarta in hematologic cancers.

Where the stock trades today

The shares of Gilead Sciences (US3755581036) trade on the Nasdaq at about $127.23 as of 06/17/2026, 16:20 Eastern Time.

Key facts on Gilead Sciences stock

• Company: Gilead Sciences, Inc.
• ISIN: US3755581036
• WKN: 885823
• Ticker: GILD
• Venue: Nasdaq
• Price (as of 06/17/2026, 16:20 Eastern Time): 127.23 USD
• Market cap: 159,000,000,000 USD (as of 06/17/2026)
• Sector / Industry: Health Care / Biotechnology
• Index membership: Standard & Poor's 500 index
• Next earnings date: 07/25/2026

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.